TxBiomed is processing Luminex assays for a service fee.

The Subcontractor shall furnish the necessary ABSL-4 non-human primate facility equipment and caging, management oversight and personnel for the performance of laboratory animal support services, and select BSL4 challenge material (filoviruses e.g. Ebola, Marburg) to test various novel compounds against filovirus infection.

TxBiomed will furnish the necessary services, qualified personnel, material, equipment and facilities to perform vaccine testing using the Sudan GP virus.

Mining recombinant antibody libraries for binders that function well together in an immunoassay is a critical component of developing diagnostics for infectious disease agents and assays for host biomarkers to study disease processes. While identifying antibodies that bind the antigen of interest is reasonably straightforward, combining them in a sandwich assay demands protein purification and in vitro modification, processes that rapidly escalate costs and time when pairing hundreds of potential clones.

The goal of this project is to piece together an effective HIV vaccine using the Simian Immunodeficiency Virus and the Varicella virus.

The goal of the program described here is to develop an antiviral drug for treating and preventing Lassa fever and other hemorrhagic fevers of arenavirus origin.

Malaria is major public health problem, causing over 1 million deaths per year worldwide. The discovery and development of new antimalarial drugs is becoming increasingly urgent as drug- resistant strains become increasingly prevalent. We propose to isolate the active antimalarial compound(s) present in the crude extracts in at least 14 previously uninvestigated plants that have promising antimalarial activity.

This research is designed to improve the quality of the research resource. Rhesus monkeys are crucial in the development of models for many human diseases. The goal of this project is to determine the factors that contribute to the development of severely abnormal Behavior in rhesus monkeys and to identify strategies for prevention and treatment.

The nature of the HIV virus has created several barriers to effective immune control by the humoral and cellular arms of adaptive immunity leading to chronic viral replication. Of the vaccine approaches tested in the SIV/macaque model, vaccination with live attenuated lentiviruses has consistently yielded the most effective and durable protection against pathogenic heterologous SIV strains. However, safety issues preclude the use of live attenuated lentiviruses in humans.

HIV and AIDS represent a critical threat to public health in the United States and internationally. This annual symposium contributes to expanding the knowledge base that will ultimately result in a vaccine to prevent transmission of HIV and treatments for those currently living with AIDS.